Calypte Biomedical Resumes Normal Production Following Previously Announced Wind-Down of Activities; Expects to Resume Shipments of Its Western Blot Test Early Next Week.

Business Editors & Health/Medical Writers

ALAMEDA, Calif.--(BW HealthWire)--June 5, 2002

Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced that the company has resumed production of both its EIA Screening and Western Blot Confirmation tests and expects to ship product to customers as early as next week following its previously announced wind-down of activities.

"The resumption of normal operations is on schedule, and we expect to have the Western Blot tests ready to ship by early next week," said Anthony Cataldo, Calypte's Executive Chairman. "Because of the shortage of our product in the market, and the critical role that it plays in confirming those who are infected with the HIV-1 virus, we are working closely with the FDA to accelerate the release time for our tests to just a few days in order to enable us to supply product to the market as quickly as possible."

Nancy Katz, president and CEO, stated, "When combined with the urine Western Blot Test, our FDA-approved urine screening test has 100% specificity in subjects previously identified as HIV-1 infected, and it is easier to administer, safer, and less expensive than conventional blood-testing. That's why it is so important to get it back into the market."

The Company retains an inventory of its urine-based EIA Screening test, and will be submitting more product to the FDA for approval in early July.

The urine Western Blot Test is used as a supplemental confirmatory test for subjects whose urine samples have been reactive in Calypte's urine-based screening test.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent filings with the SEC.